MOORESTOWN, N.J., March 01, 2017 -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), a healthcare technology company providing medication safety solutions for health plans and provider groups, has successfully implemented its first payer-based Care Transitions program focused on medication risk mitigation following discharge from a hospital or post-acute care facility. The purpose is to provide comprehensive medication reconciliation and optimization to prevent readmission due to medication problems.
According to TRHC Chairman and CEO, Calvin H. Knowlton, PhD, this member population is typically on multiple medications to treat chronic diseases. “Polypharmacy raises the chance of dangerous multi-drug interactions and serious side effects that can lead to hospital readmissions,” said Knowlton. “Our goal is to reduce risk for an adverse drug event by personalizing the member’s medication regimen to optimize pharmacotherapy treatment. We are excited to include our Medication Risk Mitigation Software Platform, MedWise Advisor®, as well as our personalized Medication Decision Support processes on behalf of the Plan members.”
The program, which launched January 1, 2017, provides a comprehensive medication reconciliation performed by Tabula Rasa HealthCare (TRHC) pharmacists in the health plan members’ homes within the first week following notification of discharges. Pharmacists perform a medication risk mitigation screening using the TRHC MedWise Advisor® software to determine medication risk. The TRHC pharmacists consult with the patient’s primary physician to discuss actual and potential risks with the goal of avoiding negative consequences. Members are provided information and documentation regarding their reconciled medication regimen and an action plan to discuss with their prescriber. As one member commented, “It was a learning experience; it made me feel like I had more control over my life instead of just doing what I was told. It made me feel like I had control over how I felt.”
TRHC’s proprietary science and technology Medication Risk Mitigation products and services perform 360-degree reviews and safety assessments of complex medication regimens, providing an innovative, alternative approach to personalized pharmacotherapy. The objective is to optimize medication use thereby improving outcomes, including reduction in falls, emergency room visits, and medication-related hospitalizations.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, please visit: www.trhc.com.
Contact: Media Dianne Semingson [email protected] T: 215-870-0829 Investors Bob East or Asher Dewhurst Westwicke Partners 443-213-0500 [email protected]


Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 



